LBA02-11 MASITINIB PLUS DOCETAXEL AS FIRST-LINE TREATMENT OF METASTATIC CASTRATE REFRACTORY PROSTATE CANCER: RESULTS FROM STUDY AB12003

Autor:	Olivier Hermine, Michel Pavic, Dominique Spaeth
Rok vydání:	2021
Předmět:	Drug Innate immune system business.industry Urology media_common.quotation_subject Masitinib medicine.disease Mast cell chemistry.chemical_compound Prostate cancer medicine.anatomical_structure Docetaxel chemistry Refractory medicine Cancer research Macrophage business medicine.drug media_common
Zdroj:	Journal of Urology. 206
ISSN:	1527-3792 0022-5347
Popis:	INTRODUCTION AND OBJECTIVE:Masitinib (MAS) is an oral, small molecule drug that targets mast cell and macrophage activity. These innate immune cells are critical components of the tumor microenviro...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::0cc574017d3cb5823a6d3544ebf856a0 https://doi.org/10.1097/ju.0000000000002149.11 Zobrazit plný text záznamu